MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$29,836K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-20,283 -58,759
Reduction in the carrying amount of rou assets, operating
377 729
Reduction in the carrying amount of rou assets, finance
80 160
Stock based compensation expense
2,651 6,768
Depreciation and amortization expense
73 122
Non-cash gain on long-term investment
0 3,390
Amortization of premium on investments in u.s. treasury securities
-60 -46
Prepaid expenses and other current assets
-2,140 2,566
Accounts payable
-15,268 13,507
Accrued expenses and other current liabilities
996 -4,822
Lease liabilities, operating
-381 -721
Lease liabilities, finance
8 -9
Net cash used in operating activities
-29,547 -48,935
Purchase of property and equipment
289 108
Purchases of investments
0 55,366
Proceeds from maturities of investments
35,300 31,900
Net cash provided by (used in) investing activities
35,011 -23,574
Proceeds from exercise of stock options
34 -
Payments on finance leases
83 281
Proceeds from common stock issuances under 2023 espp
101 170
Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement offering
0 79,999
Third-party commissions and offering costs incurred upon private placement offering-May Two Thousand Twenty Five Private Placement
0 6,917
Net cash provided by financing activities
52 72,971
Net change in cash, cash equivalents and restricted cash
5,516 462
Cash and cash equivalents at beginning of period
38,266 -
Cash and cash equivalents at end of period
44,244 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc. (LXEO)